Reuters: A panel of outside experts to the FDA, including David Blumenthal, assistant professor of medicine, unanimously voted against an experimental drug to prevent gout flares, based on trials that tested the drug for only 16 weeks. “A lot of the patients where we envision using this drug are going to take it for longer than 16 weeks. It’s hard for me to allow patients to be exposed (without longer safety data),” he said.
Medicine’s David Blumenthal sits on FDA expert panel reviewing gout drug
- Weatherhead School’s Mark Votruba talks Lake Health system
- Mandel School’s Robert Fischer discusses need for nonprofits to target youth volunteers
- Human Resources to host tax and benefits discussion
- CWRU graduate, professional programs’ ”U.S. News” rankings announced
- Educational Services for Students to offer new course for international graduate students